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Abstract
The renin-angiotensin system (RAS) plays an important role in the pathogenesis of 
inflammation and autoimmune dysfunction. Uveitis is a sight-threatening intraocular 
inflammatory disorder caused by infectious agents, autoimmune mechanisms, expo-
sure to toxins and many other unknown factors. Most components of RAS have been 
identified in every organ including the eye. The tissue-specific RAS is believed to exert 
diverse physiological effects locally independent of circulating angiotensin II (AT II) 
which functions as the effector arm of RAS causing potent proinflammatory responses 
via Angiotensin type 1 receptor (AT1R). AT II mediated stimulation of tissue factor (TF), 
the principal initiator of the clotting cascade and a major regulator of haemostasis and 
thrombosis rapidly inducible by inflammatory agents in several cell lines including 
monocytes. Activation of NFκB, a key redox-sensitive transcription factor encoding for 
the TF gene, plays a key role in that mechanism amplified by locally synthesized angio-
tensin I. (AT I) The second arm of RAS establishes systemic and local protective axis 
against inflammation and autoimmune dysfunction via angiotensin-converting enzyme 
2 (ACE2) which is a zinc-metallopeptidase able to cleave AT II to form angiotensin-(1–7) 
[AT-(1–7)]. AT-(1–7), a biologically active peptide, binds to a G-protein coupled receptor 
Mas, and activates signaling pathways that counteract the effects of AT II by negatively 
effecting inflammatory responses and negatively modulating leukocyte migration, cyto-
kine expression and release, and fibrogenic pathways. The purpose of this chapter is to 
analyze both pro-inflammatory and protective role of RAS in ocular inflammation and 
uveitis both in humans and experimental models.
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1. Introduction
The renin-angiotensin system (RAS) is a hormone system playing an important role in the 
pathogenesis of inflammation and autoimmune dysfunction [1]. RAS pathway elements 
are produced intrinsically in many diverse tissues, including the retina for controlling local 
inflammatory responses and maintaining local homeostasis [1]. While RAS is important for 
controlling normal inflammatory responses, hyperactivation of this pathway is disclosed to 
potentiate oxidative stress and inflammatory responses by the activation of nicotinamide 
adenine dinucleotide phosphate (NAD(P)H) oxidases [2]. The tissue-specific RAS is believed 
to exert diverse physiological effects locally independent of circulating angiotensin II (AT II), 
which functions as the effector arm of RAS causing potent pro-inflammatory responses via 
angiotensin type 1 receptor (AT1R) [1]. AT II is considered to stimulate tissue factor (TF), which 
induces synthesis of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
in several cell lines including monocytes [3]. The second arm of RAS is considered to estab-
lish systemic and local protective axis against inflammation and autoimmune dysfunction 
via angiotensin-converting enzyme 2 (ACE2), which cleaves AT II to angiotensin-(1–7) [2]. 
AT (1–7) is reported to counteract the effects of AT II by negatively affecting inflammatory 
responses, negatively modulating leukocyte migration, cytokine expression and release, and 
fibrogenic pathways [2].
Uveitis is considered as an intraocular inflammatory disorder caused by infectious agents 
or autoimmune mechanisms [4]. The purpose of this chapter is to analyze both pro-inflam-
matory and protective role of RAS in ocular inflammation and uveitis both in humans and 
experimental models.
2. RAS as an inflammatory cascade
Renin is considered to cleave angiotensinogen to AT1 that is further processed by ACE/ACE2 
to different AT cleavage products including AT II, which is regarded as a principle effector 
molecule of the RAS [3]. The major functions of AT II are reported to be mediated by AT1R, 
which is considered to activate directly the key signaling pathways for cell growth and hyper-
trophy [4]. AT1R has been also shown to activate NF-κB and activator protein 1 (AP-1) to 
initiate the transcription of multiple proinflammatory genes [4]. AT II is disclosed to activate 
epidermal growth factor receptors (EGFR) to induce fibronectin synthesis and transforming 
growth factor beta (TGF-β) activity to promote fibrosis and extracellular matrix formation [3]. 
The effects of circulating and tissue RAS are considered to be controlled with RAS inhibitors, 
which prevent not only hypertension but also protect tissues against injury by limiting the 
potency of deleterious inflammatory responses [3].
Recently, several studies have revealed that modulators of the RAS-including ACE inhibitors 
or AT1R antagonists display beneficial effects in the treatment of cardiovascular diseases, ath-
erosclerotic, neurodegenerative, autoimmune, and inflammatory diseases [5–8].
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3. Angiotensin II and autoimmunity
The modulatory effect of AT II on T-cell responses in autoimmune diseases has been disclosed 
by a recent study [9]. The effect of AT II in the development of Th1/Th17-mediated multiple 
sclerosis (MS) has been disclosed in experimental autoimmune encephalomyelitis (EAE)[10]. 
Elevated levels of AT II, IFN-γ, and IL-17 cytokines have been shown in the peripheral CD4+T 
cells from EAE mice [10]. AT1R is also considered to involve in experimental autoimmune 
uveitis (EAU) and experimental autoimmune myocarditis (EAM) through its effect on T-cell 
function [11]. A recent study has highlighted the role of AT1R in glomerular inflammation 
associated with autoimmune disease in mice leading to the inflammation resembling human 
systemic lupus erythematosus [12]. AT1R has also been disclosed in the pathogenesis of 
myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis 
(MOG-EAE) [13]. The expression of renin, ACE, and AT1R has been shown to be upregulated 
in macrophages, DCs, and T cells during the course of the MOG-EAE [13].
4. Angiotensin II promotes inflammation and tissue injury
Inflammatory process is considered to involve activation of the endothelium of blood vessels 
and expression of diverse endothelial cell selectins that have been shown to lead the extrava-
sation of specific leukocyte populations to the site of injury [14].
The expression and secretion of vascular endothelial growth factor (VEGF) by RAS and AT 
II have been disclosed to increase local vascular permeability [14]. AT II has also been dis-
closed to promote endothelial dysfunction through COX-2 activation, which generates vaso-
active prostaglandins and reactive oxygen species (ROS) [15]. AT II is considered to favor the 
recruitment of infiltrating inflammatory cells into tissues by stimulating the production of 
specific cytokine/chemokines. AT II has been shown to induce the production of the potent 
monocyte chemoattractant MCP-1 in cultured monocytes [15]. Elevated levels of AT II asso-
ciated with increased expression of MCP-1 and C–C chemokine receptor, CCR2, have been 
disclosed in the aorta of spontaneously hypertensive rats [16]. Modulation of MCP-1/CCR2 
via AT1R blockade has been revealed to reduce vessel inflammation in hypertensive rats [16]. 
AT II-induced macrophage infiltration in the arterial wall was shown to be virtually absent in 
CCR2-deficient mice [16]. In models of progressive nephropathies, interstitial accumulation 
of macrophages was shown to be accompanied by increased renal expression of MCP-1, and 
renoprotection was provided by the ACE inhibitor lisinopril, which was considered to reduce 
MCP-1 expression and control inflammation [17]. Dendritic cells (DCs) and highly specialized 
antigen-presenting cells (APCs) were considered to mediate the pro-inflammatory activity of 
AT II [18]. Cultured DCs have been shown to express both AT II receptors and AT II, which 
were considered to enhance DCs migration, maturation, and antigen presenting ability [18]. 
Recent study in rats with subtotal renal ablation has disclosed blockade of AT II synthesis and 
its biological activity that resulted in reduction of local DC accumulation and attenuation of 
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tubulointerstitial damage [19]. In another study considering cultured mesangial and vascular 
smooth muscle cells, AT II via AT1R signaling was shown to stimulate TLR-4 expression that 
was considered to promote cellular oxidative injury, apoptosis, and inflammation [20]. T cells 
were considered to show the pro-inflammatory effects of AT II via AT1R and endogenous 
RAS, which has been disclosed to modulate T-cell proliferation, cytoskeletal rearrangements, 
migration, and release of specific cytokines and chemokines [20].
5. Angiotensin II: role in immunosenesence
AT II is considered to stimulate the production of molecular oxygen species that trigger mito-
chondrial dysfunction and cellular injury [21]. AT II via AT1R stimulation has been shown to 
activate NAD(P)H oxidase to produce ROS, resulting in oxidative stress damage [21]. It has been 
proposed that ROSs are the most prominent molecular species involved in the aging process 
[22]. ROSs have been revealed to contribute significantly to various age-associated organ failures, 
including hypertension, cardiovascular diseases, and renal damage [22]. Hence, AT II is consid-
ered to be involved in organ senescence related to its ability to mediate the release of oxidant spe-
cies [23]. Recent studies have disclosed that AT II-induced ROS production leads to functional 
and structural changes of blood vessels that result in vascular senescence and age-related vas-
cular diseases [23]. Previous studies related to the long-term effects of AT II inhibition by either 
ACEi or ARBs disclosed protective effects on the cardiovascular system of rats and revealed the 
prolongation of the life span of rats [24, 25]. Another study disclosed that old mice lacking AT1R 
did not develop age-related cerebral circulation damage caused by the accumulation of oxygen 
radicals [26]. The inhibition of RAS has been disclosed to reverse age-related advanced myo-
cardiac hypertrophy and fibrosis in old hypertensive rats, and the protective effect presumably 
was considered to involve the suppression of AT II-mediated oxidative stress, as disclosed by 
reduced expression of NAD(P)H oxidative components in the hearts of aged rats [26].
6. Further mechanisms of angiotensin II-induced inflammation:  
human T and natural killer cells
Co-stimulatory effects of angiotensinogen, AT I, and AT II on the proliferation of T and NK 
cells have been revealed [27]. T and NK cells were considered to have RAS elements, and they 
have been synthesizing AT II at the sites of inflammation creating a potential inflammatory 
amplification system [27, 28]. Th1 immune response has been disclosed to be crucial in the 
pathogenesis of inflammatory vascular diseases [28].
However, the interaction of AT II with Th1/Th2 cytokines during the development of inflamma-
tion is considered debatable. Recent studies have demonstrated the presence of RAS elements in 
human T and NK cells that they were capable to synthesize their own AT II [29]. Renin-induced 
inflammation has been related to the binding of AT II to the renin receptor in T cells, NK cells, 
and DC [29]. AT 2R which was previously considered to antagonize the actions of the AT1R and 
having beneficial effects in hypertension, cell growth, vascular remodeling,  proliferation, and 
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inflammation, currently, it has been thought to orchestrate the collective recruitment of leuko-
cyte subsets to the sites of inflammation through mediating the effect of AT II [29, 30].
7. Clinical implications
New medical applications of RAS antagonists as anti-inflammatory and immunomodulatory 
agents without significant side-effects are being considered in the treatment of autoimmune 
diseases [31, 32].
7.1. Captopril suppresses inflammation in endotoxin-induced uveitis in rats
It has been suggested that ACEi captopril has a strong anti-ocular inflammatory effect in 
endotoxin-induced uveitis (EIU) [33]. Captopril has been shown to suppress the NF-κB activa-
tion in the iris and ciliary body cells by inhibiting the production of AT II [34]. The inhibitory 
effect of captopril on leucocyte infiltration, protein leakage, and other inflammatory markers 
in the aqueous humor including TNF-α, PGE-2, MCP-1, NO have also been revealed [35].
TNF-α is an inflammatory cytokine, which plays an important role in the recruitment of 
inflammatory cells, synthesis of other inflammatory cytokines, eicosanoids, and NO [35]. Anti 
TNF-α therapy has been used for the treatment of Behcet's disease [36]. The transcription of 
TNF-α was shown to be under the control of NF-κB [35, 36]. It has previously been disclosed 
that ACE inhibitors suppress TNF-α synthesis in vivo and in vitro and captopril was shown 
to successfully down regulate TNF-α in the aqueous humor by interfering the positive loop 
between TNF-α and NF-κB [36]. PGE2 and NO in the aqueous humor were considered to 
have profound effects on local inflammatory processes mainly by increasing vascular permea-
bility and breaking down the blood-aqueous barrier in uveitis [37]. Their concentrations in the 
aqueous humor were disclosed to be down-regulated by captopril treatment [37]. Inhibition of 
both TNF-α and PGE2/NO pathways by captopril has been shown to improve EIU in rabbits 
[38]. Another inflammatory marker MCP-1, which is under NF-κB control, is considered as 
an important mediator of monocyte infiltration. MCP-1 has been shown to be over expressed 
in human eyes during acute anterior uveitis as well as in the rat EIU model [38]. The results 
of the recent studies have disclosed that captopril successfully down-regulated MCP-1 levels 
in anterior chamber, and it showed its anti-inflammatory properties by affecting monocyte 
recruitment in EIU in rats [34, 37, 38].
The beneficial effect of AT II blockers on tissue inflammation was also considered to be related 
to the blockage of Ang II-mediated activation of Toll-like receptors (TLRs) [39]. Drugs that limit 
AT II synthesis and its biological activity, ACEi lisinopril, or ARB Candesartan were disclosed 
to result in the suppression of Th1 and Th17 cytokine release and the induction of  powerful 
antigen-specific regulatory T cells (Treg) through the modulation of the NF-κB pathway [40]. 
Administration of ARB was disclosed to suppress EAU and reduce the severity of myocardial 
lesions in EAM by inhibiting antigen-specific T-cell activation and contributing to the shift 
of Th1–Th2 immune response [41]. Chronic treatment with ACEi or ARB has been shown to 
reduce kidney damage associated with age, and the beneficial effect of RAS  inhibition was 
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considered to be related to the preservation of renal mitochondria [40]. Enalapril and losartan 
treatments have been shown to prevent the age-associated decline in the renal mitochondrial 
capacity for energy production and to attenuate the age-associated increase in mitochondrial 
oxidant production [40]. RAS inhibition was disclosed to exert a similar protective effect in 
the liver from aged rats through the maintenance of an adequate mitochondrial function by 
enhancing expression of genes responsible for mitochondrial respiration and biogenesis [41]. 
Aging is considered to be the result of chronic inflammation, and the use of RAS inhibitors or 
genetic deletion of AT1R was considered to extend the life span [41].
7.2. Oral delivery of ACE2/Ang-(1–7) bioencapsulated in plant cells protects against 
experimental uveitis and autoimmune uveoretinitis
Improving the systemic and local activity of the protective axis of the RAS by oral delivery 
of ACE2 and Ang-(1–7) bioencapsulated in plant cells has been considered as a therapeutic 
option for the ocular inflammation. Increased levels of ACE2 and Ang-(1–7) were observed in 
the retinal circulation after oral administration of ACE2 and Ang-(1–7) expressing plant cells 
[42]. Oral feeding of mice with bioencapsulated ACE2/Ang-(1–7) was shown significantly to 
reduce the incidence of EIU [42]. Treatment with bioencapsulated ACE2/Ang-(1–7) in mice 
disclosed dramatical decrease of cellular infiltration and retinal vasculitis in EAU [42]. It has 
been concluded that enhancing the protective axis of RAS by oral delivery of ACE2/Ang-(1–7) 
bioencapsulated in plant cells provide an innovative, highly efficient, and cost-effective thera-
peutic strategy for ocular inflammatory diseases [42].
8. Conclusions
Hyperactivity of the RAS resulting elevated AT II might contribute to all stages of inflam-
matory responses including ocular inflammation. ACE2 is more likely to establish a  protective 
axis of RAS involving ACE2/Ang-(1–7)/Mas, which counteract the proinflammatory and 
hypertrophic effects of the ACE/AngII/AT1R axis. AT II might have also co-stimulatory effects 
on T cells, NK cells, and DC, which have specific elements of the RAS. RAS antagonists might 
be used in conjunction with other anti-inflammatory agents as therapy for common diseases 
in which inflammation plays a major pathogenic role.
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